To the Editor: In reference to the letter by Kennedy et al, reporting two patients who tested positive to human T-lymphotropic virus I/II (HTLV-I/HTLV-II) antibodies after administration of the intravenous immunoglobulin, Octagam (Octapharma Australia, Sydney, NSW),1 the Therapeutic Goods Administration (TGA) would submit that:
- Albert Farrugia
- Office of Devices, Blood and Tissues, Therapeutic Goods Administration, Canberra, ACT.
Correspondence: albert.farrugia@health.gov.au
Responses are now closed for this article.